AstraZeneca's Lynparza-Imfinzi combo clears PhIII trial in ovarian cancer
AstraZeneca touted positive data for its Lynparza-Imfinzi blockbuster combo today with a high-level analysis from its DUO-O Phase III trial, in newly diagnosed patients with advanced high-grade epithelial ovarian cancer without tumor BRCA mutations.
In the interim analysis, AstraZeneca said that in the three-arm trial, patients treated with the Lynparza-Imfinzi combo as well as chemo and bevacizumab (Avastin) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival versus the control group, which was only treated with chemo and bevacizumab (control arm), but didn’t release specific data.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.